A case report of thalidomide in the treatment of camrelizumab-induced reactive cutaneous capillary hyperplasia

Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most prevalent immune-related adverse event observed in patients undergoing camrelizumab treatment, and there is a lack of effective therapeutic strategies. Thalidomide (THD) has anti-inflammatory, immunomodulatory, antiangiogenic...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Shujuan, Li, Cunya, Wang, Zhiying, Zhong, Zhixian, Zhong, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313310/
https://www.ncbi.nlm.nih.gov/pubmed/37390264
http://dx.doi.org/10.1097/MD.0000000000034120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313310/
https://www.ncbi.nlm.nih.gov/pubmed/37390264
http://dx.doi.org/10.1097/MD.0000000000034120

Ejemplares similares